Risk & Insurance is replacing its daily newsletter “5 Things” with a new offering, “The Risk Brief”, from November 7, 2023. This will provide curated news and original insights into the insurance and risk management profession and aims to be a concise, focused and actionable resource for industry professionals and interested readers.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
